Skip Navigation LinksHome > May 2009 - Volume 337 - Issue 5 > Pancreas Transplantation in African American Patients Using...
Text sizing:
A
A
A
American Journal of the Medical Sciences:
doi: 10.1097/MAJ.0b013e31818b0fbe
Clinical Investigation

Pancreas Transplantation in African American Patients Using Basiliximab Induction.

Zhang, Rubin MD, FASN; Florman, Sander MD, FACS; Paramesh, Anil MD, FACS; Islam, Tareq MPH; Zarifian, April NP; Simon, Eric MD; Hamm, L Lee MD, FAHA; Slakey, Douglas MD, MPH

Collapse Box

Abstract

The long-term outcome of pancreas transplant (PT) in African Americans (AA) using interleukin-2 receptor antibody induction has not been well documented. We retrospectively analyzed the 7-year outcomes of 45 AA and 73 white recipients of primary PT at our center. All PT were performed with enteric-systemic drainage. Basiliximab induction, tacrolimus, mycophenolic acid, and steroid maintenance were used as the primary immunotherapy. There was no difference by Kaplan-Meier analysis in patient (P = 0.94), pancreas graft (P = 0.76), or death-censored graft survival (P = 0.71) over 7 years between the AA and white groups. Clinically treated pancreas rejection episodes were slightly higher in AA than in white patients. Similarly, cytomegalovirus infection rates and comparable quality of graft function were noted in both groups over 7 years. Excellent long-term patient and pancreas graft survivals can be achieved in AA recipients of PT by using interleukin-2 receptor antibody induction and combination of tacrolimus, mycophenolic acid, and steroid maintenance.

© Copyright 2009 Southern Society for Clinical Investigation

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.